FDA Approves Baxter International, Inc.’s ADVATE as the Only FVIII for Routine Prophylaxis in Both Adults and Children with Hemophilia A

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. ADVATE is the only antihemophilic factor approved in the United States for prophylactic use in both adults and children.